Evidence map›Paper›PMID 26803813›Full record

ArticleBMC complementary and alternative medicine2016

The neuritogenic and neuroprotective potential of senegenin against Aβ-induced neurotoxicity in PC 12 cells.

Robert Jesky, Hailong Chen

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Fraction ofThe journal of venomous animals and toxins including tropical diseases · 2024
    Article
  3. Saponin components inFrontiers in pharmacology · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Pharmaceutical biology · 2020
    Review
  10. The seed ofPharmaceutical biology · 2020
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Robert JeskyDepartment of General Surgery-Integrated traditional Chinese and Western medicine, 1st Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Xigang District, Dalian, 116011, China.
Hailong ChenDepartment of General Surgery-Integrated traditional Chinese and Western medicine, 1st Affiliated Hospital of Dalian Medical University, No. 222, Zhongshan Road, Xigang District, Dalian, 116011, China. hailongchen2007@hotmail.com.
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImproved therapeutics aimed at ameliorating the devastating effects of neurodegenerative diseases, such as Alzheimer's disease (AD), are pertinent to help attenuate their growing prevalence worldwide. One promising avenue for such therapeutics lies in botanical medicines that have been efficaciously employed in the likes of traditional medicine doctrines for millennium. Integral to this approach is the necessity of neuritogenesis and/or neuroprotection to counterbalance the deleterious effects of amyloid-β (Aβ) proteins. Senegenin, a principle saponin of Polygala tenuifolia Willd., which has empirically shown to improve cognition and intelligence, was chosen to evaluate its cytoprotective potential and possible neuritogenic and neuroprotective effects.

methodsThe purpose of the present study was then to analyze morphological changes in neurite development and altered protein expression of two proteins requisite to neuritogenesis, growth associated protein 43 (Gap-43) and microtubule-associated protein 2 (MAP2) in PC 12 cells. Neuritogenic analysis was conducted with immunofluorescence after incubation with Aβ (25-35) peptide, and to deduce information on cell viability and mitochondrial functionality MTT (3,(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) was employed.

resultsThis study found that cells pre-incubated with senegenin for 24 h (40 μg and 20 μg/ml) before introducing Aβ attenuated Aβ-cytotoxicity, and significantly increased cell viability by 23 % and 34 % (P < 0.001), respectively. In neurite outgrowth experiments, Aβ was compared to NGF positive control and senegenin treated groups which showed a drastic decrease in the quantity, average length and maximum length of neurites (P < 0.001). At concentrations of 1 μg/ml (P < 0.01) and 5 μg/ml (P < 0.05) senegenin triggered neuritogenesis with significant increases in total neurite number, average length and maximum length. This was additionally shown through the augmented expression of MAP2 and Gap-43.

conclusionsThese results suggest that senegenin possesses cytoprotective properties, can moderate neurite outgrowth and augment MAP2 and Gap-43, thus suggesting a potential therapeutic value for Polygala tenuifolia in neurodegenerative disorders.

Indexed as

Amyloid beta-PeptidesAnimalsCell SurvivalCytoprotectionDrugs, Chinese HerbalMolecular StructureNeuritesNeuroprotective AgentsNeurotoxinsPC12 CellsPeptide FragmentsPolygalaRatsAmyloid beta-Peptidesamyloid beta-protein (25-35)Drugs, Chinese HerbalNeuroprotective AgentsNeurotoxinsPeptide Fragmentstenuigenin

Identifiers

PMID26803813
PMCPMC4724108
OpenAlexW2258659272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.